MétaCan
Menu
Back to cohort
Record W4413836646 · doi:10.1111/bju.16913

Defining statistical cure in patients with T1 high‐grade non‐muscle‐invasive bladder carcinoma treated with BCG immunotherapy

2025· article· en· W4413836646 on OpenAlexaff
José Daniel Subiela, Irene de la Parra, Javier Taborda, A. Artiles Medina, Renate Pichler, Wojciech Krajewski, C. Mínguez Ojeda, A. Fernandez Mardomingo, P. Del Olmo Duran, E. Lopez Perez, Daniel A. González‐Padilla, Júlia Aumatell, Keiichiro Mori, Pietro Scilipoti, Mattia Longoni, Mario de Angelis, J. Caño-Velasco, A. Lafuente Puentedura, L. Polanco Pujol, Roberto Contieri, Andrea Gallioli, Andrzej Tukiendorf, David D’Andrea, Jeremy Yuen‐Chun Teoh, Luca Afferi, Francesco Del Giudice, Gautier Marcq, Simone Albisinni, Francesco Soria, Laura S. Mertens, Ekaterina Laukhtina, Karl H. Tully, Andrea Mari, Félix Guerrero‐Ramos, Mario Álvarez‐Maestro, C.J. Martin, Franklin Anagua Melendres, Oscar Buisán, José Agustín López‐González, José L. Domínguez-Escrig, Javier Aranda, José Luis Rodríguez Elena, Giuseppe Basile, Marco Moschini, Benjamin Pradère, Eduardo Albers Acosta, F. Lozano Palacio, Albert Carrión, Pablo Gajate, Ana Sáiz, Paolo Gontero, F.J. Burgos Revilla

Bibliographic record

VenueBritish Journal of Urology · 2025
Typearticle
Languageen
FieldMedicine
TopicBladder and Urothelial Cancer Treatments
Canadian institutionsMcGill University Health Centre
Fundersnot available
KeywordsImmunotherapyMedicineCarcinomaOncologyUrologyInternal medicineCancer

Abstract

fetched live from OpenAlex

OBJECTIVE: To assess cure fraction and conditional survival probabilities for oncological outcomes in patients with T1 high-grade (T1HG) non-muscle-invasive bladder carcinoma (NMIBC) treated with adequate Bacillus Calmette-Guérin (BCG) immunotherapy. PATIENTS AND METHODS: This multi-institutional retrospective cohort study included 1403 patients with T1HG NMIBC treated between 2007 and 2020, adhering to modern guidelines including mandatory second transurethral resection of bladder tumour and adequate BCG, defined as at least five of six induction doses and at least two of three maintenance doses. Cure fraction, defined as the proportion of patients who will never experience the event of interest, was calculated for recurrence-free survival (RFS), progression-free survival (PFS), cancer-specific survival (CSS) and overall survival (OS) using a mixture cure model. Conditional survival probabilities over 5 years were also computed. RESULTS: Cure fractions were 41% (95% confidence interval [CI] 36%-46%) for RFS, 71% (95% CI 65%-76%) for PFS, 76% (95% CI 70%-83%) for CSS, and 38% (95% CI 28%-49%) for OS. Patients in very-high-risk subgroups, according to the European Association of Urology risk stratification, showed significantly lower cure fractions, particularly for PFS (61% [95% CI 50%-72%]) and CSS (59% [95% CI 34-84%]). Conditional survival analysis demonstrated that patient prognoses improved over time, with 5-year conditional RFS, PFS, CSS and OS probabilities exceeding 90% for patients who were event-free at 5 years from diagnosis. CONCLUSIONS: We found that BCG immunotherapy achieves a statistical cure in select T1HG NMIBC patients, with avoidance of progression to muscle-invasive bladder carcinoma in approximately 70% of cases. The probability of experiencing any adverse oncological event (recurrence, progression or death) is less than 10% among patients who remain event-free for 5 years.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.006
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.008

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.006
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.001
Bibliometrics0.0010.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.001
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.005
GPT teacher head0.233
Teacher spread0.228 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueBritish Journal of UrologySame topicBladder and Urothelial Cancer TreatmentsFrench-language works237,207